These metrics, and several others, help EYE earn a Value grade of B, while SRDX has been given a Value grade of C.Д®YE is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. SRDX currently has a PEG ratio of 17.27.ДЄnother notable valuation metric for EYE is its P/B ratio of 4.58. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. We also note that EYE has a PEG ratio of 2.23. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.Д®YE currently has a forward P/E ratio of 51.41, while SRDX has a forward P/E of 172.68. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. But this is just one piece of the puzzle for value investors. Investors should feel comfortable knowing that EYE likely has seen a stronger improvement to its earnings outlook than SRDX has recently. National Vision and SurModics are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Fundamental company data provided by Morningstar, updated daily.Investors interested in Medical - Products stocks are likely familiar with National Vision (EYE) and SurModics (SRDX). Stock quotes provided by InterActive Data. The gurus listed in this website are not affiliated with, LLC. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Past performance is a poor indicator of future performance. In no event shall be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on, or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Gurus may be added or dropped from the GuruFocus site at any time. The individuals or entities selected as 'gurus' may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. This investment adviser does not provide advice to individual investors. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. is not operated by a broker or a dealer.

Srdx analysis